Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors

Texto completo
Autor(es):
Mostrar menos -
Bidinotto, Lucas Tadeu ; Veo, Carlos A. R. ; Loaiza, Edgar Aleman ; Santos De Franca, Alessandra Paulino ; Lorenzi, Adriana Tarla ; Reis Rosa, Luciana Albina ; De Oliveira, Cristina Mendes ; Levi, Jose Eduardo ; Scapulatempo-Neto, Cristovam ; Longatto-Filho, Adhemar ; Reis, Rui Manuel
Número total de Autores: 11
Tipo de documento: Artigo Científico
Fonte: MOLECULAR MEDICINE REPORTS; v. 14, n. 4, p. 3791-3797, OCT 2016.
Citações Web of Science: 1
Resumo

Anal cancer is a rare type of digestive tract disease, which has had a crescent incidence in a number of regions. Carcinomas are most frequently found, with squamous cell carcinoma (SCC) comprising similar to 95% of all anal tumors. The major risk factor for development of this type of tumor is human papillomavirus (HPV) infection. However, previous studies have identified patients with anal cancer that are HPV-/p16-and observed that they have a poorer outcome compared with HPV+/p16+ patients. This suggests that molecular profile may drive anal cancer progression. The aim of the present study was to evaluate the mutational status of two important oncogenes, KRAS and BRAF, in a series of anal cancer lesions. Resected tumors of the anal canal (n=43) were evaluated, nine of these were high-grade squamous intra-epithelial lesion cases (HSIL), 11 were adenocarcinomas, and 23 SCCs. Direct sequencing of KRAS proto-oncogene, GTPase (KRAS; codons 12 and 13) and B-Raf proto-oncogene, serine/threonine kinase (BRAF; codon 600) was performed and associated with patient clinicopathological and molecular features. There was a trend of poorer prognosis of adenocarcinoma compared with HSIL and SCC. Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation. It was observed that, these mutations are rare in anal tumors, and certain patients may be at a disadvantage using targeted therapies based on KRAS and BRAF mutational status. As there is a low mutation percentage in SCCs, adenocarcinomas and HSIL, there may exist other underlying molecular alterations that result in anal cancer development, which require further elucidation. (AU)

Processo FAPESP: 11/08523-7 - Perfil de alterações cromossômicas em tumores cerebrais (meduloblastomas e gliomas): impacto na identificação de novas vias tumorigênicas
Beneficiário:Lucas Tadeu Bidinotto
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 10/16795-4 - Rastreamento de biomarcadores e do Papilomavírus humano em raspado celular de canal anal: correlação com infecção concomitante em colo uterino, cavidade oral e orofaringe
Beneficiário:Adhemar Longatto Filho
Linha de fomento: Auxílio à Pesquisa - Regular